Total submissions: 55
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| International Society for Gastrointestinal Hereditary Tumours |
RCV000076807 | SCV000108292 | likely pathogenic | Lynch syndrome | 2019-06-21 | reviewed by expert panel | curation | >2 MSI tumours; deficient protein function inferred from 2 independent assays |
| Dasa | RCV000200994 | SCV007598247 | pathogenic | not provided | 2026-02-02 | criteria provided, single submitter | clinical testing | NM_000535.7(PMS2):c.137G>T (p.Ser46Ile) is a missense variant that results in the substitution of serine with isoleucine. Functional evidence supports a deleterious effect on the gene or gene product (PMID: 15256438; PMID: 16619239; PMID: 23709753; PMID: 18602922; PMID: 24027009). This variant has been recurrently observed in individuals with related phenotype (PMID: 15256438; PMID: 16619239; PMID: 23709753; PMID: 18602922; PMID: 24027009). The variant is present at low frequency in population datasets. Based on the available data, this variant is classified as pathogenic. |
| Genetics Laboratory, |
RCV004691720 | SCV007595799 | pathogenic | Inherited MMR deficiency (Lynch syndrome) | 2026-03-16 | criteria provided, single submitter | clinical testing | PP3_supporting, PS3_supporting, PM3_strong, PP4_strong |
| Cambridge Genomics Laboratory, |
RCV004691720 | SCV007131609 | pathogenic | Inherited MMR deficiency (Lynch syndrome) | 2025-12-10 | criteria provided, single submitter | clinical testing | PS4_Very Strong,PP3_Moderate |
| NHS Central & South Genomic Laboratory Hub | RCV004691720 | SCV007114062 | pathogenic | Inherited MMR deficiency (Lynch syndrome) | 2025-12-08 | criteria provided, single submitter | clinical testing | |
| Clinical Genomic Analysis |
RCV000056324 | SCV006586749 | likely pathogenic | Lynch syndrome 4 | 2025-08-20 | criteria provided, single submitter | research | PMS2 c.137G>T, p.(Ser46Ile), is a missense variant predicted to alter a single conserved amino acid in the encoded protein from a serine to an isoleucine. This variant has been classified as likely pathogenic by the International Society for Gastrointestinal Hereditary Tumours (InSiGHT) expert panel. |
| Spanish MMR Variant Interpretation Working Group | RCV000115657 | SCV006306110 | pathogenic | Hereditary cancer-predisposing syndrome | 2025-05-05 | criteria provided, single submitter | clinical testing | The PMS2 variant c.137G>T replaces serine with isoleucine at codon 46 of the PMS2 protein, p.(Ser46Ile). The serine residue is highly conserved, and there is a large physicochemical difference between serine and isoleucine. It has been reported as a founder mutation of likely European origin (Tomsic 2013 PMID 22577899). It has an allele frequency of 0.028% in the gnomAD v4.1.0 database, with a maximal credible allele frequency of 0.032% (BS1 is not applied because it is a founder variant). It is a missense variant with a MAPP+PolyPhen-2 prior probability of pathogenicity of >0.81 (PP3_M); and SpliceAI, SSF, MaxEnt, NNSPLICE, and GeneSplicer algorithms suggest no impact on splicing. No effect on splicing has been reported for this variant in in vitro mRNA assays (Nakagawa 2004 PMID 15256438; van der Klift 2010 PMID 20186688). There are no other described PAT/LPAT variants classified by InSiGHT located at the same residue. Functional assays at the protein level demostrated abrogated MMR function, proficient expression and nuclear localization (PMID: 23709753, 24027009) (PS3). This variant has been reported in several patients/families with Lynch syndrome-associated cancers (in many cases isolated loss of PMS2 was detected in the tumors) as well as in patients with constitutional MMR deficiency (CMMRD) syndrome who also have a second pathogenic PMS2 mutation (in many of these cases PMS2 loss in normal tissues was documented) (Clendenning 2006 PMID 16619239, Senter 2008 PMID 18602922 , Herkert 2011 21376568, Tomsic 2013 PMID 22577899, Borras 2013 PMID 23709753, van der Klift 2016 PMID 27435373; InSiGHT database) (PP4_strong; PM3 is not applied because PM2 is not fulfilled). It has been reported in our Spanish cohort in a patient affected with CRC showing PMS2 loss of expression. The variant co-segregated with disease in a family (LR>4; Insight data, PMID 23709753, 21204794, and internal data; PP1_M). Based on the available evidence, this variant is classified as Pathogenic (Class 5). |
| Molecular Pathology, |
RCV000056324 | SCV006276915 | pathogenic | Lynch syndrome 4 | 2024-03-26 | criteria provided, single submitter | clinical testing | |
| Clinical Genetics Laboratory, |
RCV000200994 | SCV005197212 | likely pathogenic | not provided | 2024-03-26 | criteria provided, single submitter | clinical testing | |
| Genomics and Molecular Medicine Service, |
RCV004691720 | SCV005196392 | pathogenic | Inherited MMR deficiency (Lynch syndrome) | 2024-06-14 | criteria provided, single submitter | clinical testing | PS4_Very Strong,PM3_Strong,PP3,PP4_Strong |
| Center for Genomic Medicine, |
RCV000200994 | SCV005090751 | likely pathogenic | not provided | 2025-03-04 | criteria provided, single submitter | clinical testing | |
| Clinical Genomics Laboratory, |
RCV004555831 | SCV005045097 | pathogenic | Dilated cardiomyopathy 1G; Hypertrophic cardiomyopathy 9 | 2023-11-15 | criteria provided, single submitter | clinical testing | The PMS2 c.137G>T (p.Ser46Ile) variant has been reported in a number individuals affected with Lynch syndrome (Borras E et al., PMID: 23709753; Senter L et al., PMID: 18602922; Tosmic J et al., PMID: 22577899) or mismatch repair cancer syndrome (Agostini M et al., PMID: 16144131; Herkert JC et al., PMID: 21376568; Leenen CHM et al., PMID: 21204794) and is reported to segregate with disease in families. Functional studies show deficient mismatch repair activity, indicating that this variant impacts protein function (Borras E et al., PMID: 23709753; Drost M et al., PMID: 24027009; van der Klift HM et al., PMID: 27435373). This variant resides within the nucleotide binding pocket of the ATPase domain, suggesting an interference with the ATPase function (Borras E et al., PMID: 23709753). Another variant in the same codon, c.137G>A (p.Ser46Asn), has been reported in affected individuals with Lynch syndrome and is considered pathogenic (Everett JN et al., PMID: 25006859; Haraldsdottir S et al., PMID: 26866578, ClinVar Variation ID: 91301). The highest population minor allele frequency in the population database genome aggregation database (v.2.1.1) is 0.03% in Latino/Admixed American population. Computational predictors indicate that the variant is damaging, evidence that correlates with impact to PMS2 function. This variant has been reported in the ClinVar database as a pathogenic variant by 20 submitters and likely pathogenic by 16 submitters (ClinVar Variation ID: 9245). Based on available information and the ACMG/AMP guidelines for variant interpretation (Richards S et al., PMID: 25741868), this variant is classified as pathogenic. |
| All of Us Research Program, |
RCV000076807 | SCV004842155 | pathogenic | Lynch syndrome | 2024-09-27 | criteria provided, single submitter | clinical testing | The c.137G>T (p.Ser46Ile) variant in the PMS2 gene is located on the exon 2 and is predicted to replace serine with isoleucine at codon 46 (p.Ser46Ile). The variant has been reported in more than 10 unrelated individuals affected with Lynch syndrome in heterozygous state (PMID: 18602922, 27435373, 21204794, 32634176). A different missense variant affecting the same amino acid (p.Ser46Asn) has been interpreted as pathogenic (ClinVar ID: 91301). The variant has been reported in more than 10 unrelated individuals with constitutional mismatch repair-deficiency (CMMRD) syndrome in homozygous or compound heterozygous states (PMID: 21204794, 32642664, 26318770). The variant was detected in trans with other pathogenic variants (p.Pro246fs, p.Arg578fs) in individuals with CMMRD (ClinVar ID: 91366, 9244, PMID: 21204794, 32642664). Experimental studies showed this variant resulted in impaired mismatch repair activity and negative functional impact on the protein (PMID: 23709753, 24027009). The variant is reported in ClinVar (ID: 9245). Computational prediction algorithms suggest a deleterious impact for this variant (REVEL score 0.939). Therefore, the c.137G>T (p.Ser46Ile) variant of PMS2 has been classified as pathogenic. |
| Institute for Biomarker Research, |
RCV000115657 | SCV004228118 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2023-09-12 | criteria provided, single submitter | clinical testing | |
| Mayo Clinic Laboratories, |
RCV000200994 | SCV004223967 | pathogenic | not provided | 2025-01-31 | criteria provided, single submitter | clinical testing | PP3_moderate, PP4_strong, PM3_very_strong, PS3 |
| Baylor Genetics | RCV000056324 | SCV004205401 | pathogenic | Lynch syndrome 4 | 2024-03-25 | criteria provided, single submitter | clinical testing | |
| Laboratorio de Genetica e Diagnostico Molecular, |
RCV000056324 | SCV004183374 | likely pathogenic | Lynch syndrome 4 | 2020-07-07 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PS3, PS4, PM1, PM2, PM3 |
| Rady Children's Institute for Genomic Medicine, |
RCV003335023 | SCV004046408 | pathogenic | PMS2-related cancer disorders | criteria provided, single submitter | clinical testing | This variant has been reported in the heterozygous state in individuals affected with Lynch syndrome-associated cancers (PMID: 15256438, 16619239, 18602922, 23709753, 28596308, 30702970, 31992580) and in the homozygous or compound heterozygous state in individuals affected with constitutional mismatch repair deficiency syndrome (CMMRD) (PMID: 16144131, 17557300, 21204794, 21376568). In vitro experimental studies have shown that this variant impairs the mismatch repair activity of PMS2 (PMID: 23709753, 24027009). The c.137G>T(p.Ser46Ile) variant is present in the heterozygous state in the gnomAD population database at a frequency of 0.017% (48/277180) and is absent in the homozygous state. The c.137G>T(p.Ser46Ile) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.137G>T(p.Ser46Ile) variant is classified as Pathogenic. | |
| St. |
RCV000056324 | SCV004031230 | pathogenic | Lynch syndrome 4 | 2025-06-17 | criteria provided, single submitter | clinical testing | The PMS2 c.137G>T p.(Ser46Ile) missense change has a maximum subpopulation frequency of 0.028% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a deleterious effect on protein function, and functional studies support that the variant impairs mismatch repair activity (PMID: 23709753). This variant has been observed in several individuals with features consistent with Lynch syndrome and constitutional mismatch repair deficiency, including tumors that have demonstrated microsatellite instability and/or loss of PMS2 by immunohistochemistry (PMID: 17557300, 18273873, 19156169, 19283792, 20205264). In summary, this variant meets criteria to be classified as pathogenic. |
| Myriad Genetics, |
RCV000056324 | SCV004019868 | pathogenic | Lynch syndrome 4 | 2023-04-05 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 26116798, 26318770, 17557300, 32642664, 30608896]. Functional studies indicate this variant impacts protein function [PMID: 24027009, 23709753, 27435373, 30608896, 17557300]. This variant is expected to disrupt protein structure [Myriad internal data]. |
| Laan Lab, |
RCV001804723 | SCV002538616 | likely pathogenic | Lynch syndrome 1 | 2021-05-01 | criteria provided, single submitter | research | |
| Ce |
RCV000200994 | SCV002497503 | pathogenic | not provided | 2026-03-01 | criteria provided, single submitter | clinical testing | PMS2: PS3, PS4, PM5 |
| Genetic Services Laboratory, |
RCV000200994 | SCV002072174 | likely pathogenic | not provided | 2018-09-24 | criteria provided, single submitter | clinical testing | DNA sequence analysis of the PMS2 gene demonstrated a sequence change, c.137G>T, in exon 2 that results in an amino acid change, p.Ser46Ile. The p.Ser46Ile change affects a highly conserved amino acid residue located in a domain of the PMS2 protein that is known to be functional. The p.Ser46Ile substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL), and has been described in the EXAC database with a low population frequency of 0.013% (dbSNP rs121434629). This particular amino acid change has been described in the literature in the homozygous and compound heterozygous states in patients with autosomal recessive constitutional mismatch repair deficiency syndrome (PMIDs: 21204794, 16144131, 21376568). This variant was also reported in 2 members of a family affected with lynch syndrome associated colorectal and skin tumors, and bladder cancer (PMID: 23709753). In vitro functional assays demonstrate decreased mismatch repair activity for the Ser46Ile variant compared to wild type (PMID: 23709753). |
| CHEO Genetics Diagnostic Laboratory, |
RCV001797999 | SCV002042783 | likely pathogenic | Breast and/or ovarian cancer | 2022-05-02 | criteria provided, single submitter | clinical testing | |
| Revvity Omics, |
RCV000200994 | SCV002018884 | pathogenic | not provided | 2024-08-26 | criteria provided, single submitter | clinical testing | |
| Institute for Clinical Genetics, |
RCV000200994 | SCV002009116 | likely pathogenic | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
| Clinical Genetics and Genomics, |
RCV000200994 | SCV001450303 | likely pathogenic | not provided | 2016-02-05 | criteria provided, single submitter | clinical testing | |
| Mendelics | RCV000056324 | SCV001137331 | likely pathogenic | Lynch syndrome 4 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV000076807 | SCV000918033 | pathogenic | Lynch syndrome | 2017-11-21 | criteria provided, single submitter | clinical testing | Variant summary: The PMS2 c.137G>T (p.Ser46Ile) variant involves the alteration of a conserved nucleotide that results in a missense change within the nucleotide binding pocket of the ATPase domain (Borras 2013). 4/4 in silico tools predict a damaging outcome for this variant (SNPsandGO not captured due to low reliability index). Functional studies have shown the variant to cause deficient MMR activity (Borras 2013, Drost 2013, van der Klift 2016). This variant was found in 47/271742 control chromosomes (in gnomAD and publication controls), however the technology utilized for the gnomAD dataset does not rule out pseudogene interference and thus this data cannot be relied upon. This variant has been reported in several patients/families with Lynch syndrome-associated cancers (in many cases isolated loss of PMS2 was detected in the tumors) as well as in patients with constitutional MMR deficiency (CMMR-D) syndrome who also have a second pathogenic PMS2 mutation (in many of these cases PMS2 loss in normal tissues was documented) (Clendenning 2006, Senter 2008, Herkert_2011, Tomsic 2013, Borras 2013, van der Klift 2016). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. |
| Fulgent Genetics, |
RCV002476951 | SCV000894431 | pathogenic | Lynch syndrome 4; Mismatch repair cancer syndrome 4 | 2024-06-08 | criteria provided, single submitter | clinical testing | |
| St. |
RCV000722017 | SCV000853190 | likely pathogenic | Pituitary carcinoma | 2016-03-18 | criteria provided, single submitter | clinical testing | This is a missense variant in which a G is replaced by a T at coding position 137 and is predicted to change a Serine to an Isoleucine at codon 46. |
| Human Genome Sequencing Center Clinical Lab, |
RCV000056324 | SCV000840051 | pathogenic | Lynch syndrome 4 | 2018-04-10 | criteria provided, single submitter | clinical testing | This c.137G>T (p.S46I) variant in PMS2 has been reported in individuals with mismatch repair deficiency syndrome, colon, endometrial, colorectal and bladder cancer (PMID: 21376568, 16144131, 21204794, 22577899, 16619239, 23709753). In addition, functional studies have shown that the c.137G>T (p.S46I) variant significantly impairs mismatch repair activity (PMID: 23709753, 24027009). Therefore, the c.137G>T (p.S46I) in the PMS2 gene is classified as pathogenic. |
| Equipe Genetique des Anomalies du Developpement, |
RCV000056324 | SCV000803859 | likely pathogenic | Lynch syndrome 4 | 2017-04-19 | criteria provided, single submitter | clinical testing | |
| Color Diagnostics, |
RCV000115657 | SCV000686122 | pathogenic | Hereditary cancer-predisposing syndrome | 2025-01-02 | criteria provided, single submitter | clinical testing | This missense variant replaces serine with isoleucine at codon 46 in the nucleotide binding pocket of the ATPase domain of the PMS2 protein. Computational prediction tool suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >=0.7, PMID: 27666373). Functional studies have shown that this variant significantly impairs the mismatch repair activity of PMS2 protein (PMID: 23709753, 24027009). This variant has been reported in over 50 individuals affected with Lynch syndrome or Lynch syndrome-associated cancers (PMID: 15256438, 16619239, 18602922, 23709753, 28596308, 30702970, 31992580) and is thought to be a founder mutation in the Caucasian population (PMID: 22577899, 25345868). This variant has been reported in trans with pathogenic PMS2 variants in individuals affected with constitutional mismatch repair deficiency syndrome (PMID: 16144131, 17557300, 21204794, 21376568). This variant has been identified in 454/1610770 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. |
| ARUP Laboratories, |
RCV000200994 | SCV000604885 | pathogenic | not provided | 2025-02-27 | criteria provided, single submitter | clinical testing | The PMS2 c.137G>T; p.Ser46Ile variant (rs121434629) is published in the literature in individuals and families with Lynch syndrome-associated cancers and constitutional mismatch repair-deficiency (Auclair 2007, Borras 2013, Jackson 2008, Senter 2008, Tosmic 2013). This variant is reported as pathogenic or likely pathogenic by multiple laboratories in ClinVar (Variation ID: 9245) and is found in the Latino population with an overall allele frequency of 0.03% (11/35,326 alleles) in the Genome Aggregation Database. Several individuals with constitutional mismatch repair-deficiency carried this variant in trans to a pathogenic PMS2 variant (Auclair 2007, Jackson 2008, Senter 2008), including another variant at the same codon, p.Ser46Asn, observed in two affected individuals (Jackson 2008, Senter 2008). The serine at codon 46 is highly conserved and both the p.Ser46Ile and p.Ser46Asn variants exhibit less than 10% of wild-type activity in mismatch repair in vitro assays (Borras 2013, Drost 2013). Based on available information, this variant is considered to be pathogenic. References: Auclair J et al. Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation. Hum Mutat. 2007 Nov;28(11):1084-90. Borras E et al. Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants. J Med Genet. 2013 Aug;50(8):552-63. Drost M et al. Inactivation of DNA mismatch repair by variants of uncertain significance in the PMS2 gene. Hum Mutat. 2013 Nov;34(11):1477-80. Jackson CC et al. Cafe-au-lait macules and pediatric malignancy caused by biallelic mutations in the DNA mismatch repair (MMR) gene PMS2. Pediatr Blood Cancer. 2008 Jun;50(6):1268-70. Senter L et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008 Aug;135(2):419-28. Tomsic J et al. Recurrent and founder mutations in the PMS2 gene. Clin Genet. 2013 Mar;83(3):238-43. |
| Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000200994 | SCV000601815 | pathogenic | not provided | 2024-08-20 | criteria provided, single submitter | clinical testing | The PMS2 c.137G>T (p.Ser46Ile) variant has been reported in the published literature in multiple individuals and families affected with Lynch syndrome (PMIDs: 30702970 (2019), 21239990 (2011), 20205264 (2010), 18602922 (2008), 18273873 (2008), 16144131 (2005)) and CMMRD syndrome (PMIDs: 36360190 (2022), 30608896 (2019), 21376568 (2011), 19156169 (2009)). In addition, experimental studies have shown this variant causes significantly reduced DNA mismatch repair activity in vitro (PMIDs: 30608896 (2019), 24027009 (2013), 23709753 (2013)). The frequency of this variant in the general population, 0.00054 (27/49562 chromosomes in North-Western European subpopulation (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is higher than would generally be expected for pathogenic variants in this gene. However, using published studies, the variant was determined to be enriched in affected individuals. Based on the available information, this variant is classified as pathogenic. |
| Illumina Laboratory Services, |
RCV000056324 | SCV000469744 | likely pathogenic | Lynch syndrome 4 | 2016-09-27 | criteria provided, single submitter | clinical testing | Across a selection of the available literature, the PMS2 c.137G>T (p.Ser46Ile) missense variant has been identified in at least 18 heterozygous or compound heterozygous cases with various cancers and three as-yet unaffected heterozygous family members (Agostini et al. 2005; Auclair et al. 2007; Senter et al. 2008; Pastrello et al. 2011; Herkert et al. 2011; Tomsic et al. 2013; Borras et al. 2013). The p.Ser46Ile variant was absent from 188 control individuals and 436 control chromosomes but is reported at a frequency of 0.00022 in the European (non-Finnish) population of the Exome Aggregation Consortium. The variant occurs at a strongly conserved residue in an important functional domain. Borras et al. (2013) demonstrated through in vitro expressions studies that the p.Ser46Ile variant had significantly reduced mismatch repair activity, approximately 13% that of wild type, while Drost et al. (2013) showed that the p.Ser46Ile variant had a mismatch repair efficiency similar to that of a known pathogenic variant. Based on the evidence, the p. Ser46Ile variant is classified as likely pathogenic for Lynch syndrome. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |
| Laboratory for Molecular Medicine, |
RCV000076807 | SCV000271259 | pathogenic | Lynch syndrome | 2024-03-06 | criteria provided, single submitter | clinical testing | The p.Ser46Ile variant in PMS2 has been described as a founder variant for Lynch syndrome in Caucasians (Ponti 2015 PMID:25345868, Tomsic 2013 PMID:22577899). It has been reported in the heterozygous state in >15 individuals with Lynch syndrome-associated cancers, where the tumors showed microsatellite instability and loss of PMS2 expression in some individuals (Borras 2013 PMID:23709753, Clendenning 2006 PMID:16619239, Cock-Rada 2017 PMID:28528518, Haraldsdottir 2013 PMID:25194673, Le 2017 PMID:28596308, Nakagawa 2004 PMID:15256438, Pritchard 2016 PMID:27433846, Senter 2008 PMID:18602922, Tomsic 2013 PMID:22577899, ClinVar: Variation ID 9245). This variant has also been reported in the biallelic state (homozygous or compound heterozygous with a second pathogenic variant) in at least 9 individuals with constitutional mismatch repair deficiency syndrome (CMMRD) and segregated with disease in at least 3 affected relatives from at least 2 families (Auclair 2007 PMID:17557300, Borras 2013 PMID:23709753, Giunti 2009 PMID:19156169, Herkert 2011 PMID:21376568). Normal and tumor tissue from some individuals with CMMRD showed loss of expression of PMS2 (Agostini 2005 PMID:16144131, Auclair 2007 PMID:17557300, Bodo 2015 PMID:26116798, Giunti 2009 PMID:19156169, Herkert 2011 PMID:21376568, Jackson 2008 PMID:18273873, Lavoine 2015 PMID:26318770, Pastrello 2011 PMID:21239990, Stark 2014 PMID:24897087). Additionally, some relatives who were heterozygous carriers of this variant were clinically unaffected, suggesting reduced penetrance. In vitro functional studies provide some evidence that the p.Ser46Ile variant may impact protein function (Borras 2013 PMID:23709753, Drost 2013 PMID:24027009, Nakagawa 2004 PMID:15256438). This variant has been identified in 0.04% (416/1179868) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org, v.4.0.0). Although this variant has been seen in the general population, its frequency is low enough to be consistent with the frequency and penetrance of PMS2-associated Lynch syndrome. Computational prediction tools and conservation analysis suggest that the p.Ser46Ile variant may impact the protein. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant Lynch syndrome (ACMG/AMP Criteria applied: PS3; PS4; PP1; PP3) and for autosomal recessive CMMRD (ACMG/AMP Criteria applied: PM3_Very_strong; PS3; PP1; PP3). |
| Vantari Genetics | RCV000115657 | SCV000267076 | pathogenic | Hereditary cancer-predisposing syndrome | 2016-01-26 | criteria provided, single submitter | clinical testing | |
| University of Washington Department of Laboratory Medicine, |
RCV000076807 | SCV000266116 | likely pathogenic | Lynch syndrome | 2015-11-20 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV000524432 | SCV000253845 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2026-02-03 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 46 of the PMS2 protein (p.Ser46Ile). This variant is present in population databases (rs121434629, gnomAD 0.03%). This missense change has been observed in individual(s) with constitutional mismatch repair deficiency syndrome (CMMR-D) (PMID: 16144131, 16619239, 21204794, 21376568, 22577899, 23709753). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. Invitae Evidence Modeling of clinical and family history, age, sex, and reported ancestry of multiple individuals with this PMS2 variant has been performed. This variant is expected to be pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model that incorporates the clinical features of 1,627,235 individuals referred to our laboratory for PMS2 testing. ClinVar contains an entry for this variant (Variation ID: 9245). Invitae Evidence Modeling incorporating data from in vitro experimental studies (internal data) indicates that this missense variant is expected to disrupt PMS2 function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects PMS2 function (PMID: 23709753, 24027009). For these reasons, this variant has been classified as Pathogenic. |
| Eurofins Ntd Llc |
RCV000200994 | SCV000227140 | likely pathogenic | not provided | 2015-02-27 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV000115657 | SCV000184825 | pathogenic | Hereditary cancer-predisposing syndrome | 2025-02-17 | criteria provided, single submitter | clinical testing | The p.S46I pathogenic mutation (also known as c.137G>T), located in coding exon 2 of the PMS2 gene, results from a G to T substitution at nucleotide position 137. The serine at codon 46 is replaced by isoleucine, an amino acid with dissimilar properties. This mutation has been identified in numerous individuals with a tumor exhibiting microsatellite instability and/or loss of PMS2 expression by immunohistochemistry and has been associated with a significant reduction in mismatch repair activity (Clendenning M et al. Hum. Mutat. 2006 May;27:490-5; Borras E et al. J. Med. Genet. 2013 Aug;50:552-63; Drost M et al. Hum. Mutat. 2013 Nov;34:1477-80; Dudley B et al. Am. J. Surg. Pathol. 2015 Aug;39:1114-20). The p.S46I mutation has been reported in a homozygous state or in conjunction with a second PMS2 mutation in multiple individuals with phenotypes consistent with constitutional mismatch repair-deficiency (CMMR-D) (Auclair J et al. Hum. Mutat. 2007 Nov;28:1084-90; Senter L et al. Gastroenterology. 2008 Aug;135:419-28; Pastrello C et al. Genet. Med. 2011 Feb;13:115-24; Herkert JC et al. Eur. J. Cancer. 2011 May;47:965-82; Lavoine N et al. J. Med. Genet. 2015 Nov;52:770-8; Rengifo-Cam W et al. ACG Case Rep. J. 2017 Mar;4:e34). Data supports p.S46I as a founder mutation of likely European origin (Tomsic J et al. Clin. Genet. 2013 Mar;83:238-43). Based on the available evidence, this alteration is classified as a pathogenic mutation. |
| Gene |
RCV000200994 | SCV000149566 | pathogenic | not provided | 2020-04-30 | criteria provided, single submitter | clinical testing | Observed in individuals in the heterozygous state with a personal or family history consistent with pathogenic variants in this gene and reported as a Caucasian founder variant (Nakagawa 2004, Agostini 2005, Clendenning 2006, Auclair 2007, Jackson 2008, Senter 2008, Van der Klift 2010, Herkert 2011, Leenen 2011, Tomsic 2013, Lavoine 2015, Ponti 2015, ten Broeke 2015, Heath 2016, van der Klift 2016, Nowak 2017, Rengifo-Cam 2017); Published functional studies demonstrate a damaging effect: in vitro cell-free complementation assays showed deficient mismatch repair activity as well as reduced PMS2 expression (Nakagawa 2004, Borras 2013, Drost 2013); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25871621, 20186688, 25980754, 26110232, 25345868, 25512458, 28286799, 28528518, 25194673, 22949387, 15256438, 16144131, 16619239, 17557300, 18273873, 18602922, 21376568, 21204794, 22577899, 26318770, 26808570, 27435373, 27863258, 30155321, 23709753, 24027009, 11574484, 24055113, 25637381, 21239990, 26940435, 26143115, 26895986, 26976419, 27433846, 26681312, 28514183, 28365877, 26845104, 28873162, 28904067, 28125078, 27806231, 28152038, 28449805, 26556299, 30013564, 25186627, 29875428, 30702970, 30612635, 31857677, 32060697, 31992580, 31447099, 31433215, 31948886, 31589614, 32719484, 32571878, 33258288, 32634176, 33504652) |
| Prevention |
RCV003390667 | SCV004121118 | pathogenic | PMS2-related disorder | 2024-07-12 | no assertion criteria provided | clinical testing | The PMS2 c.137G>T variant is predicted to result in the amino acid substitution p.Ser46Ile. This variant has been reported as a founder variant in European populations (Table 1, Senter et al. 2008. PubMed ID: 18602922; Tomsic et al. 2013. PubMed ID: 22577899; Table 1 and Figure 2, Wang et al. 2020. PubMed ID: 31992580). It has been reported in the heterozygous state in individuals with Lynch syndrome spectrum cancers (Clendenning et al. 2006. PubMed ID: 16619239; Fanale et al. 2022. PubMed ID: 35223509; Table S1, S3, Susswein et al. 2016. PubMed ID: 26681312; Tomsic et al. 2013. PubMed ID: 22577899; Cock-Rada et al. 2018. PubMed ID: 28528518; Brohl et al. 2017. PubMed ID: 28125078; Table S4, Hartman. 2020. PubMed ID: 32782288; Hechtman et al. 2020. PubMed ID: 31857677). This variant has also been reported in the homozygous and compound heterozygous states in individuals with autosomal recessive constitutional mismatch repair-deficiency syndrome (Agostini et al. 2005. PubMed ID: 16144131; Table 1, Herkert et al. 2011. PubMed ID: 21376568). Of note, this variant has also been reported in cis (on the same allele) with a second pathogenic PMS2 variant, c.164–1G>A, in individuals with autosomal dominant Lynch syndrome and is referred to as the c.[137G>T; 164-1G>A] allele (Table 1 and Figure 2, Wang et al. 2020. PubMed ID: 31992580). The c.137G>T (p.Ser46Ile) variant is reported in 0.031% of alleles in individuals of Latino descent in gnomAD and is interpreted as pathogenic and likely pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/9245/). This variant, in isolation or as the c.[137G>T; 164-1G>A] allele, is interpreted as pathogenic. |
| OMIM | RCV000056324 | SCV002601716 | pathogenic | Lynch syndrome 4 | 2013-08-01 | no assertion criteria provided | literature only | |
| Gene |
RCV001804723 | SCV002054088 | not provided | Lynch syndrome 1 | no classification provided | literature only | ||
| Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000200994 | SCV001976325 | likely pathogenic | not provided | no assertion criteria provided | clinical testing | ||
| Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000200994 | SCV001956600 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
| Clinical Genetics, |
RCV000200994 | SCV001918197 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
| Laboratory of Diagnostic Genome Analysis, |
RCV000200994 | SCV001800634 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
| Counsyl | RCV000056324 | SCV000677739 | likely pathogenic | Lynch syndrome 4 | 2015-05-14 | no assertion criteria provided | clinical testing | This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. |
| Department of Pathology and Laboratory Medicine, |
RCV001353458 | SCV000592923 | pathogenic | Endometrial carcinoma | no assertion criteria provided | clinical testing | The PMS2 p.Ser46Ile variant was identified in 11 of 1466 proband chromosomes (frequency: 0.008) from individuals or families with hereditary breast and ovarian cancer syndrome or Lynch syndrome and was not identified in 2490 control chromosomes from healthy individuals (Bodo 2017, Borras 2013, Clendenning 2006, Senter 2008, Pastrello 2011, Dorschner 2013, Nakagawa 2004). The variant was also identified in dbSNP (ID: rs121434629) as “With Pathogenic, Uncertain significance allele”, ClinVar (classified as pathogenic by GeneDx, Ambry Genetics, Invitae, and 8 other submitters; and as likely pathogenic by InSiGHT expert panel in 2014 and 7 other submitters), COGR (2x), Insight Colon Cancer Gene Variant Database (1x as class 4), Mismatch Repair Genes Variant Database (4x), and Insight Hereditary Tumors Database (25x). The variant was not identified in Cosmic or Zhejiang Colon Cancer Database. The variant was identified in control databases in 48 of 277180 chromosomes at a frequency of 0.0002 (Genome Aggregation Consortium Feb 27, 2017), in the following populations: Latino in 11 of 35326 chromosomes (frequency: 0.0003) and European in 37 of 125388 chromosomes (frequency: 0.0003); it was not identified in the African, Other, Ashkenazi Jewish, East Asian, Finnish, or South Asian populations. The variant was identified in several cases with CMRD or Turcot syndrome as a biallelic variant with one of the following PMS2 variants: c.1951C>T, c.2174+1G>A, c.804-2A>G, and c.137G>A (Agostini 2005, Herkert 2011, Giunti 2009, Jackson 2008, Senter 2008). The variant is located within the functional domain of histidine kinase-like ATPase, increasing the likelihood that it may have clinical significance. Functional assays have shown that this variant had reduced mismatch repair efficiency (Drost 2013) and resulted in near absence of the PMS2 protein (Auclair 2007). One study suggests that this variant may by a founder mutation in a population of undetermined ancestry (Tomsic et al 2013). This variant has also been identified by our laboratory in two patients affected with Lynch syndrome and PMS2-deficient colon tumours. The p.Ser46 residue is conserved across mammals and other organisms, and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that this variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. In summary, based on the above information, this variant meets our laboratory’s criteria to be classified as pathogenic. | |
| CSER _CC_NCGL, |
RCV000009826 | SCV000190470 | pathogenic | Mismatch repair cancer syndrome 1 | 2014-06-01 | no assertion criteria provided | research | |
| OMIM | RCV001267878 | SCV000030047 | pathogenic | Mismatch repair cancer syndrome 4 | 2013-08-01 | no assertion criteria provided | literature only |